Xuepei Y. Zhang

No. 1 Jianshe East Road
Zhengzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 47 publications

Cognitive Versus Software-based Fusion Targeted Biopsy for the Diagnosis of Clinically Significant Prostate Cancer: A Multicenter, Randomized, Noninferiority Trial (IMAGINATION).

Cognitive Versus Software-based Fusion Targeted Biopsy for the Diagnosis of Clinically Significant Prostate Cancer: A Multicenter, Randomized, Noninferiority Trial (IMAGINATION).

Journal: European urology

Published: April 29, 2026

Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial.

Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 08, 2025

Suction mini-percutaneous nephrolithotomy versus standard percutaneous nephrolithotomy for the management of 2-4 cm kidney stones: study protocol for an international, multicenter, parallel-group, noninferiority, randomized controlled trial.

Suction mini-percutaneous nephrolithotomy versus standard percutaneous nephrolithotomy for the management of 2-4 cm kidney stones: study protocol for an international, multicenter, parallel-group, noninferiority, randomized controlled trial.

Journal: World journal of urology

Published: August 31, 2025

Vitamin C-functionalized copper nanozymes for treating drug-resistant intracellular infections and hyperinflammation.

Vitamin C-functionalized copper nanozymes for treating drug-resistant intracellular infections and hyperinflammation.

Journal: Materials today. Bio

Published: August 13, 2025

Multimodal deep learning model for AI-based functional prognostic risk stratification in patients undergoing radical nephrectomy.

Multimodal deep learning model for AI-based functional prognostic risk stratification in patients undergoing radical nephrectomy.

Journal: Nature communications

Published: July 31, 2025

Exploring the underlying mechanisms of Hedyotis diffusa and Scutellaria Barbata herb pair on the prognosis and treatment efficacy of bladder cancer patients: an integrated approach of network pharmacology and bioinformatics analysis.

Exploring the underlying mechanisms of Hedyotis diffusa and Scutellaria Barbata herb pair on the prognosis and treatment efficacy of bladder cancer patients: an integrated approach of network pharmacology and bioinformatics analysis.

Journal: BMC complementary medicine and therapies

Published: May 23, 2025

Robot-assisted surgical strategies for inferior vena cava thrombus with special morphology: How to balance tumor control and functional preservation?

Robot-assisted surgical strategies for inferior vena cava thrombus with special morphology: How to balance tumor control and functional preservation?

Journal: Chinese medical journal

Published: May 18, 2025

ACSL5 regulated acetyl-CoA to promote bladder cancer cellular senescence via 53BP1 acetylation.

ACSL5 regulated acetyl-CoA to promote bladder cancer cellular senescence via 53BP1 acetylation.

Journal: Oncogene

Published: January 10, 2025

Correction 2 for: Taurine suppresses ROS-dependent autophagy via activating Akt/mTOR signaling pathway in calcium oxalate crystals-induced renal tubular epithelial cell injury.

Correction 2 for: Taurine suppresses ROS-dependent autophagy via activating Akt/mTOR signaling pathway in calcium oxalate crystals-induced renal tubular epithelial cell injury.

Journal: Aging

Published: January 03, 2025

Development and validation of a prediction score for subtype diagnosis of primary aldosteronism.

Development and validation of a prediction score for subtype diagnosis of primary aldosteronism.

Journal: Chinese medical journal

Published: December 21, 2024

A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer.

A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer.

Journal: BMC medicine

Published: October 14, 2024

Correlation of PSA and survival in metastatic hormone-sensitive prostate cancer treated with rezvilutamide plus ADT in the CHART trial.

Correlation of PSA and survival in metastatic hormone-sensitive prostate cancer treated with rezvilutamide plus ADT in the CHART trial.

Journal: Med (New York, N.Y.)

Published: May 17, 2024

Showing 1-12 of 47

Last Updated: 09/26/2026